Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
Pluri Inc. (PLUR) has secured an additional $3.5 million investment from Merchant Adventure Fund, L.P., a major existing shareholder, bringing total recent financings to $10 million. The investment follows a recent $6.5 million private placement with global investor Alejandro Weinstein.
The new investment involves issuing 759,219 common shares at $4.61 per share and warrants to purchase 45,553 shares at $5.568 per share. The closing is expected around February 20, 2025. The recent $6.5 million investment from Weinstein includes an agreement to acquire Kokomodo and potentially enter the cacao market.
The funds will support Pluri's growth strategy as a global leader in cell-based technology, enabling expansion across pharma, foodtech, and agtech industries. The company views this additional investment as a strong vote of confidence in its vision, technology, and execution strategy.
Pluri Inc. (PLUR) ha ottenuto un ulteriore investimento di 3,5 milioni di dollari da Merchant Adventure Fund, L.P., un importante azionista esistente, portando il totale dei recenti finanziamenti a 10 milioni di dollari. L'investimento segue un recente collocamento privato di 6,5 milioni di dollari con l'investitore globale Alejandro Weinstein.
Il nuovo investimento prevede l'emissione di 759.219 azioni ordinarie a 4,61 dollari per azione e di warrent per acquistare 45.553 azioni a 5,568 dollari per azione. La chiusura è prevista attorno al 20 febbraio 2025. Il recente investimento di 6,5 milioni di dollari da Weinstein include un accordo per acquisire Kokomodo e potenzialmente entrare nel mercato del cacao.
I fondi supporteranno la strategia di crescita di Pluri come leader globale nella tecnologia basata sulle cellule, consentendo un'espansione nei settori farmaceutico, foodtech e agtech. L'azienda considera questo investimento aggiuntivo come un forte segnale di fiducia nella sua visione, tecnologia e strategia di esecuzione.
Pluri Inc. (PLUR) ha asegurado una inversión adicional de 3.5 millones de dólares del Merchant Adventure Fund, L.P., un importante accionista existente, llevando el total de financiamientos recientes a 10 millones de dólares. La inversión sigue a un reciente colocación privada de 6.5 millones de dólares con el inversor global Alejandro Weinstein.
La nueva inversión involucra la emisión de 759,219 acciones comunes a 4.61 dólares por acción y opciones para adquirir 45,553 acciones a 5.568 dólares por acción. Se espera que el cierre ocurra alrededor del 20 de febrero de 2025. La reciente inversión de 6.5 millones de dólares de Weinstein incluye un acuerdo para adquirir Kokomodo y potencialmente entrar en el mercado de cacao.
Los fondos apoyarán la estrategia de crecimiento de Pluri como un líder global en tecnología celular, permitiendo la expansión en las industrias farmacéutica, foodtech y agtech. La empresa considera esta inversión adicional como un fuerte voto de confianza en su visión, tecnología y estrategia de ejecución.
Pluri Inc. (PLUR)는 주요 기존 주주인 Merchant Adventure Fund, L.P.로부터 350만 달러의 추가 투자를 확보하여 최근 투자 총액을 1000만 달러로 늘렸습니다. 이 투자는 글로벌 투자자인 Alejandro Weinstein과의 최근 650만 달러의 사모 배정에 뒤따릅니다.
새로운 투자는 주당 4.61달러에 759,219주의 보통주를 발행하고, 주당 5.568달러에 45,553주를 매입할 수 있는 워런트를 포함합니다. 거래 마감은 2025년 2월 20일 경으로 예상됩니다. Weinstein의 최근 650만 달러 투자는 Kokomodo 인수와 카카오 시장 진출 가능성에 대한 계약을 포함합니다.
이 자금은 Pluri가 제약, 푸드테크 및 애그테크 산업 전반에 걸쳐 확장을 가능하게 하는 세포 기반 기술의 글로벌 리더로서 성장 전략을 지원합니다. 회사는 이 추가 투자를 비전, 기술 및 실행 전략에 대한 확고한 신뢰의 표시로 보고 있습니다.
Pluri Inc. (PLUR) a sécurisé un investissement supplémentaire de 3,5 millions de dollars de Merchant Adventure Fund, L.P., un actionnaire important, portant le total des financements récents à 10 millions de dollars. Cet investissement fait suite à un placement privé récent de 6,5 millions de dollars avec l'investisseur mondial Alejandro Weinstein.
Le nouvel investissement implique l'émission de 759,219 actions ordinaires à 4,61 dollars par action et de bons de souscription pour acheter 45,553 actions à 5,568 dollars par action. La clôture est prévue autour du 20 février 2025. Le récent investissement de 6,5 millions de dollars de Weinstein comprend un accord pour acquérir Kokomodo et potentiellement entrer sur le marché du cacao.
Les fonds soutiendront la stratégie de croissance de Pluri en tant que leader mondial dans la technologie cellulaire, permettant une expansion dans les secteurs pharmaceutique, foodtech et agtech. L'entreprise considère cet investissement supplémentaire comme un fort vote de confiance dans sa vision, sa technologie et sa stratégie d'exécution.
Pluri Inc. (PLUR) hat eine zusätzliche Investition von 3,5 Millionen US-Dollar von Merchant Adventure Fund, L.P., einem wichtigen bestehenden Aktionär, gesichert, wodurch die Gesamtfinanzierungen der letzten Zeit auf 10 Millionen US-Dollar steigen. Die Investition folgt auf eine kürzliche Privatplatzierung von 6,5 Millionen US-Dollar mit dem globalen Investor Alejandro Weinstein.
Die neue Investition umfasst die Ausgabe von 759.219 Stammaktien zu je 4,61 US-Dollar pro Aktie sowie Optionen zum Kauf von 45.553 Aktien zu 5,568 US-Dollar pro Aktie. Der Abschluss wird um den 20. Februar 2025 erwartet. Die kürzliche Investition von 6,5 Millionen US-Dollar von Weinstein beinhaltet eine Vereinbarung zur Übernahme von Kokomodo und möglicherweise den Einstieg in den Kakaomarkt.
Die Mittel werden Pluris Wachstumsstrategie als globalen Marktführer in der zellbasierten Technologie unterstützen, wodurch eine Expansion in den Bereichen Pharma, Foodtech und Agtech ermöglicht wird. Das Unternehmen sieht diese zusätzliche Investition als ein starkes Zeichen des Vertrauens in seine Vision, Technologie und Ausführungsstrategie.
- Secured $3.5M investment at premium price ($4.61 vs market)
- Total recent financing reached $10M in two weeks
- Investment from existing major shareholder indicates confidence
- Strategic expansion into cacao market through Kokomodo acquisition
- Potential dilution from issuance of 759,219 new shares
- Additional potential dilution from 45,553 warrant shares
Insights
This $3.5 million investment from Merchant Adventure Fund, priced at
The warrant structure, offering additional purchase rights at
This $10 million total raise provides important operational runway and strategic flexibility. In the current challenging biotech funding environment, securing investments at a premium from existing shareholders is particularly noteworthy. The structure of these investments - combining straight equity with warrant coverage - offers a balanced approach to dilution while providing upside potential for investors.
The timing aligns with Pluri's expansion into new verticals, including the pending Kokomodo acquisition for entry into the cacao market. This diversification strategy, backed by fresh capital, positions Pluri to leverage its cell-based technology platform across multiple high-value markets including pharma, foodtech and agtech.
- New investment follows recent private placement of
$6.5 million with global investor and entrepreneur, Mr. Alejandro Weinstein - Funds are intended to support Pluri’s growth and execution strategy as a global leader in cell-based technology
HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the pricing of a private placement of
Pursuant to a securities purchase agreement between the Company and Merchant Adventure Fund, L.P., the Company has agreed to issue and sell 759,219 shares of the Company’s common shares, at a purchase price of
With this latest commitment, Pluri has successfully secured a total of
The Company believes that the continued investment from a major, long-term shareholder is a strong vote of confidence in Pluri’s vision, technology, and execution strategy. These funds are expected to support the Company’s growth as a global leader in cell-based technology, reinforcing its ability to expand across multiple industries, including pharma, foodtech, and agtech.
“I believe that the additional investment from one of our largest shareholders reaffirms the strength of Pluri’s strategy and the trust of our long-term investors in our ability to execute,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We believe that we are well-positioned to advance our mission of leveraging our cell-based technology platform to revolutionize multiple industries.”
The Company believes that this investment further strengthens Pluri’s financial position as it continues to drive innovation, scale its platform, and unlock new market opportunities.
The securities described above were offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the regenerative medicine, foodtech and agtech fields. The Company also offers Contract Development and Manufacturing Organization services. Pluri establishes partnerships that are aimed to leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expected closing of the offering, the receipt of the proceeds and the intended use of the proceeds from the offering, the belief that the investment is a strong vote of confidence in Pluri’s vision, technology, and execution strategy and its ability to execute. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: the conditions to the closing of the Transactions, including shareholder approval, may not be met; the parties may not successfully negotiate final documentation with respect to the Kokomodo Transaction; the expected benefits from the Transactions may not be realized; changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.
Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com
FAQ
How much did Pluri (PLUR) raise in their latest investment round in February 2025?
What is the share price for Pluri's (PLUR) February 2025 private placement?
How many new shares will Pluri (PLUR) issue in the February 2025 investment?
What markets is Pluri (PLUR) planning to expand into with the new funding?
When is the closing date for Pluri's (PLUR) $3.5M private placement?
